Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01663935 · ClinicalTrials.gov registry record · Phase 2
Vision Response to Dopamine Replacement
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01663935 is a Phase 2 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 20 participants.
The verdict
NCT01663935, a Phase 2 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate and document physiologic and functional changes in visual performance and retinal function of patients diagnosed with albinism (a dopamine deficiency state) following a trial of oral Levodopa/carbidopa treatment.
Interventions
- DRUG Levodopa/carbidopa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-10-17 |
| Est. Completion | 2018-04-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01663935
The ClinicalTrials.gov registry entry for NCT01663935 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Levodopa/carbidopa is the first listed.
NCT01663935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01663935 about?
NCT01663935 is a clinical study titled "Vision Response to Dopamine Replacement". The purpose of the study is to evaluate and document physiologic and functional changes in visual performance and retinal function of patients diagnosed with albinism (a dopamine deficiency state) following a trial of oral Levodopa/carbidopa treatment.
What is the current status of trial NCT01663935?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2012-10-17. Estimated completion is 2018-04-12.
What interventions are being tested in trial NCT01663935?
The interventions under investigation include: Levodopa/carbidopa (DRUG).
Who is sponsoring clinical trial NCT01663935?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.